I think this secondary eliminates the prospects for a sale of the company.You don't dilute if there's a sale on the horizon.
If it is good news, I have my doubts. Every short share just covered at a fixed price no possibility of a squeeze.Will see if they mention it at the conference presentation tomorrow afternoon.
It takes money to make money. I bet this money is for manufacturing purposes. And the amount reflects the demand for Glatopa... it is huge!... k
i'm finally able to post on my username kamoa_1 after a couple of weeks of not being able to... I've been using my other username, mauibeachbum_1 to post... k
Launch still months away- price action seams to show this fact. I went and listened to the oral arguments Momenta made to court of appeals case number 14-1274. Very, very weak in my opinion. Doubt very much anything from Amphestar or early resolution from Teva. JMHO With that said September will be nice.
One of the new things revealed on BoA presentation... ASCO Chicago.... data on abstract is up to January 15... Data that will presented on June 1 will be up to April... k
presentation is canned but fine... it is the question and answer part that is interesting.... a properly worded question can elicit an off the cuff answer that is revealing... I was enlightened on a couple of things... not a waste of my time listening to it... k
Results: As of January 15, 2015, 39 pts in 7 cohorts (0.5 and 1 mg/kg + gem; 1, 2, 4, 6, and 5 mg/kg + nabP + gem) received necu. Two dose-limiting toxicities (DLTs) occurred: increased AST/ALT at 0.5 mg/kg necu (N = 1) and cellulitis at injection site at 6 mg/kg (N = 1). Mild aPTT increases were observed at 4-6 mg/kg. There were no increases in known AEs of chemotherapy across doses. PK data (Cmax, AUC) increased linearly from 2 mg/kg. Release of heparin-binding proteins (e.g. HGF, a PD marker) from heparan sulfate stores increased with dose and plateaued at 4-5 mg/kg. Given the cellulitis and mild aPTT increases at 6 mg/kg, 5 mg/kg was considered MTD. 16 pts treated with necu + nabP + gem completed Cycle 1 and had ≥ 1 scan on treatment; 8 (50%) achieved RECIST partial response and 6 (38%) more achieved stable disease, for an overall disease control rate of 14/16 (88%). Of 15 CA19.9 evaluable pts, 15 (100%) had 20%, 14 (93%) had 50%, and 7 (47%) had 90% decreases from baseline. Conclusions: The MTD was necu 5 mg/kg combined with nabP + gem. Acceptable tolerability and encouraging signals of activity were observed with the combination. These results supported the initiation of the randomized, double-blind, phase II trial. Clinical trial information: NCT01621243
ASCO website Abstract #4114
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.
Eileen Mary O'Reilly, MD
Poster Board: #225 Release time 5pm EST presentation to follow on June 1 2015
Expect some info to be discussed at B of A Conference, later today. Listen to Web cast.
today's close above the two other $20 closing prices in APR imply accumulation and shares at this level beginning to dry up. I'm not up on the science here, I am a chartist first and foremost and I specialize in distressed equities as well as obvious breakout patterns.
This one is about to head higher, much higher. GL
No downers please... I'm having such a good time with this nose bleed height... k
Copaxone approval and 6 other bio similars in devel- how much are those products worth let alone the science to continue to develop,( Novartis and Biogen ) think this would become bidding war..